Vigamox - instructions for use, analogs, reviews and release forms (eye drops 0.5%) drugs for the treatment of conjunctivitis, including Chlamydia in adults, children (including infants) and pregnancy. Composition

In this article, you can read the instructions for using the drug Vigamox. Presented are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors specialists on the use of Vigamox in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Vigamox in the presence of existing structural analogues. Use for the treatment of conjunctivitis, including chlamydial and chronic in adults, children (including infants), as well as during pregnancy and lactation. Composition of the preparation.

Vigamox - fluoroquinolone antibacterial preparation of 4 generations, has a bactericidal effect. It is active against a wide range of gram-positive and gram-negative microorganisms, anaerobic, acid-fast and atypical bacteria.

The mechanism of action is associated with the inhibition of topoisomerase 2 (DNA gyrase) and topoisomerase 4. DNA-gyrase is an enzyme involved in the replication, transcription and repair of bacterial DNA. Topoisomerase 4 is an enzyme involved in the cleavage of chromosomal DNA during the division of a bacterial cell.

There is no cross-resistance with macrolides, aminoglycosides and tetracyclines. It was reported about the development of cross-resistance between the systemically used moxifloxacin and other fluoroquinolones.

Moxifloxacin is active against most strains of microorganisms:

Gram-positive bacteria: Corynebacterium spp., Including Corynebacterium diphtheriae; Micrococcus luteus; Staphylococcus aureus; Staphylococcus epidermidis (staphylococcus); Staphylococcus haemolyticus; Staphylococcus hominis; Staphylococcus warneri; Streptococcus mitis; Streptococcus pneumoniae; Streptococcus (streptococcus) of the viridans group.

Gram-negative bacteria: Acinetobacler Iwoffii; Haemophilus influenzae; Haemophilus parainfluenzae; Klebsiella spp (Klebsiella).

Other microorganisms: Chlamydia trachomatis (chlamydia).

Moxifloxacin acts against most of the below listed microorganisms, but the clinical significance of this data is not known:

Gram-positive bacteria: Listeria monocytogenes; Staphylococcus saprophyticus; Streptococcus agalactiae; Streptococcus mitis; Streptococcus pyogenes; Streptococcus group C, G, F;

Gram-negative bacteria: Acinetobacler baumannii; Acinetobacter calcoaceticus; Citrobacter freundii; Citrobacter koseri; Enterobacter aerogenes; Enterobacter cloacae; Escherichia coli; Klebsiella oxytoca; Klebsiella pneumoniae; Moraxella catarrhalis; Morganella morganii; Neisseria gonorrhoeae; Proteus mirabilis; Proteus vulgaris; Pseudomonas stutzeri;

Anaerobic microorganisms: Clostridium perfringens; Fusobacterium spp .; Prevotella spp .; Propionibacterium acnes.

Other organisms: Chlamydia pneumoniae; Legionella pneumophila (Legionella); Mycobacterium avium (mycobacterium); Mycobacterium marinum; Mycoplasma pneumoniae.

Composition

Moxifloxacin + excipients.

Indications

• bacterial conjunctivitis (including chronic form) caused by micro-organisms sensitive to moxifloxacin.

Forms of release

Eye drops 0.5%.

Instructions for use and how to use them

Locally. Adults and children older than 1 year instilled 1 drop in the affected eye 3 times a day. Usually, the condition improves after 5 days and treatment should be continued in the next 2-3 days. If the condition does not improve after 5 days, the question of the correctness of the diagnosis and / or the prescribed treatment should be raised. The duration of treatment depends on the severity of the condition and the clinical and bacteriological course of the disease.

Side effect

• pain;
• irritation and itching in the eye;
• dry eye syndrome;
• hyperemia of the conjunctiva;
• hyperemia of the eye;
• defect of the epithelium of the cornea;
• point keratitis;
• subconjunctival hemorrhage;
• conjunctivitis;
• swelling of the eye;
• a feeling of discomfort in the eyes;
• blurring of vision;
• decreased visual acuity;
• erythema eyelids;
• unusual sensations in the eye;
• headache;
• decrease in hemoglobin of blood;
• a feeling of discomfort in the nose;
• pharyngolaryngeal pain;
• sensation of foreign body in the throat;
• nausea, vomiting;
• ulcerative keratitis;
• corneal erosion;
• the formation of corneal defects;
• increased intraocular pressure;
• corneal opacity;
• corneal infiltrates;
• deposits on the cornea;
• allergic reactions of the eye;
• corneal edema;
• photophobia;
• blepharitis;
• swelling of the eyelids;
• increased tear;
• discharge from the eyes;
• palpitation;
• dizziness;
• dyspnea;
• rash;
• itching of the skin;
• hypersensitivity.

Contraindications

• hypersensitivity to any of the components of the drug or to other quinolones;
• the period of breastfeeding;
• children under 1 year.

Application in pregnancy and lactation

Sufficient experience in the use of the drug during pregnancy and during lactation there. The use of the drug during pregnancy (category C by FDA) is possible only if the expected therapeutic effect for the mother exceeds the potential risk to the fetus and the child.Vigamox can enter the breast milk, therefore, breast-feeding for the period of drug treatment should be discontinued.

Teratogenicity

In pre-clinical studies in animals, moxifloxacin did not have a teratogenic effect at doses of 500 mg / kg per day (approximately 21,700 times the recommended daily dose for humans). However, there was a slight decrease in fetal body weight and a delay in the development of the musculoskeletal system. Against the background of a dose of 100 mg / kg per day there was an increase in the frequency of decrease in the growth of newborns.

Use in children

Vigamox can be used in pediatrics in children from 1 year in doses similar to adults. Neonatal is not used.

special instructions

Patients who used systemic preparations of the quinolone series experienced severe, in some cases fatal hypersensitivity reactions (anaphylaxis), sometimes immediately after the first dose (!).

Some reactions were accompanied by collapse, loss of consciousness, Quinck's edema (including laryngeal and / or face swelling), airway obstruction, dyspnoea, urticaria and skin itching. If these conditions occur, resuscitation may be required.

Prolonged use of antibiotic can lead to excessive growth of non-susceptible microorganisms, including fungi. In case of superinfection, it is necessary to cancel the drug and prescribe adequate therapy.

Do not touch the tip of the dropper bottle to any surface to avoid contamination of the vial and its contents. The bottle must be closed after each use.

Impact on the ability to drive vehicles and manage mechanisms

After application of the drug, a temporary decrease in the clarity of visual perception is possible, and before its restoration it is not recommended to drive and engage in activities requiring increased attention and reaction.

Drug Interactions

The interaction of locally prescribed Vigamox with other medications has not been studied.

Data are known for the oral dosage form of moxifloxacin: no clinically significant drug interactions (unlike other fluoroquinolone formulations) with theophylline, warfarin, digoxin, oral contraceptives, probenecid, Ranitidine and glibenclamide have been reported.

In studies, moxifloxacin does not inhibit the isoenzymes CYP3A4, CYP2D6, CYP2C9 or CYP1A2, which may indicate that moxifloxacin does not change the pharmacokinetic properties of drugs metabolized by cytochrome P450 isoenzymes.

Analogues of the drug Vigamox

Structural analogs for the active substance:

• Avelox;
• Aquamox;
• Mossimak;
• Moxin;
• Moxinspiration;
• Moxifloxacin;
• Moxifloxacin hydrochloride;
• Moxifur;
• Plevilox;
• Rotomox;
• Heynemox.

Analogues on the curative effect (remedies for the treatment of conjunctivitis):

• Arthromax;
• Vitabakt;
• Garamycin;
• Gentamicin;
• Hydrocortisone;
• Histalong;
• Dexamethasone;
• Zanotsin;
• Ilozon;
• Innolier;
• Colbiocin;
• Levomycetin;
• Liprokhin;
• Maxidex;
• Maxitrol;
• Midrim;
• Naklof;
• Okatsin;
• Okulokhel;
• Ofloxacin;
• Plivasept;
• Poludan;
• Prenatsid;
• Sulfacil sodium (Albucide);
• Tebridex;
• Tobrex;
• Totatsef;
• Uniflox;
• Floxal;
• Furacilin;
• Fucitalmic;
• Cefetrexyl;
• Cephezole;
• Ceftidine;
• Ciloxane;
• Ciprosan;
• Ciprofloxacin;
• Cifloxinal;
• Chibroxin;
• Hermitsed.

Similar medicines:

Other medicines: